Drug Trial Radar · NCT02578602
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
Last checked: Nov 20, 2026Latest source record: Oct 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Oct 2010
Primary completion
Nov 2014
Study completion Jun 2015
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not yet known whether MRI with gadoxetate disodium provides a more precise measurement of liver tumors than standard computed tomography (CT).
Conditions
- Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
- BCLC Stage 0 Adult Hepatocellular Carcinoma
- BCLC Stage A Adult Hepatocellular Carcinoma
- BCLC Stage B Adult Hepatocellular Carcinoma
- BCLC Stage C Adult Hepatocellular Carcinoma
- BCLC Stage D Adult Hepatocellular Carcinoma
- Localized Non-Resectable Adult Liver Carcinoma
- Localized Resectable Adult Liver Carcinoma
Interventions
Gadoxetate DisodiumDrug
Given IV
Magnetic Resonance ImagingDevice
Undergo MRI with gadoxetate disodium
Primary outcomes
What the sponsor says the trial is designed to measure.
- Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring "size" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variabilityTime frame: Up to 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.